GlaxoSmithKline Partners with Singapore for Formulation - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

GlaxoSmithKline Partners with Singapore for Formulation


GlaxoSmithKline (GSK) and the Institute of Chemical and Engineering Sciences (ICES) of Singapore’s Agency for Science, Technology and Research’s have signed a five-year strategic agreement to develop new evidence-based formulations (EBFs) specifically for emerging markets. .EBFs are often fixed-dose combinations of active drugs or new formulations with different pharmacokinetic properties, new routes of delivery, or improved safety profiles. ICES has a long standing relationship with GSK since 2003, and the development of EBFs will further strengthen the relationship between both parties. The collaboration leverages ICES’ strengths and expertise in synthesis, formulation and process development and GSK’s vast experience in drug-candidate selection, optimization, and product development in novel formulations. The collaboration will enhance ICES’ technical expertise and know-how in drug product formulation, analytical techniques, development and scale-up. It will develop a pool of local expertise in specialized formulation for pharmaceutical development in Singapore.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here